Chemomab Therapeutics Ltd. (CMMB)
NASDAQ · Manufacturing · Pharmaceutical preparations
$2.16−$0.0400 (−1.82%) on the dayAs of the close; data may be delayed.
CMMB price, last 12 months
Key stats
- Previous close
- $2.20
- Open
- $2.20
- Day range
- $2.10 – $2.26
- 52-week range
- $1.35 – $3.58
- Volume
- 63.2K
- Avg volume (20 days)
- 96.2K
- Market cap
- $15.8M
Performance
1W−17.2%
1M−16.6%
3M+35.9%
6M+39.4%
YTD+30.9%
1Y−16.9%
vs S&P 500, 1Y−33.7 pts
Technicals and fundamentals
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $15.8M